Research programme: cancer vaccines - immatics biotechnologies/Roche

Drug Profile

Research programme: cancer vaccines - immatics biotechnologies/Roche

Alternative Names: Colorectal cancer ImmunoBody vaccines - immatics/Scancell; Gastric cancer vaccine - immatics; IMA 930; IMA 942; IMA 962; Non-small cell lung cancer vaccine - immatics; TUMAP-based cancer vaccines - immatics/Roche

Latest Information Update: 05 Jul 2017

Price : $50

At a glance

  • Originator immatics biotechnologies GmbH
  • Developer immatics biotechnologies GmbH; Roche
  • Class Cancer vaccines; Peptide vaccines; Peptides
  • Mechanism of Action T lymphocyte stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Research Prostate cancer
  • No development reported Gastric cancer; Non-small cell lung cancer

Most Recent Events

  • 26 Jun 2017 Scancell has patent protection for DNA ImmunoBody® platform technology in European Union
  • 16 Jul 2016 No recent reports of development identified for preclinical development in Gastric-cancer in Germany (Intradermal, Injection)
  • 16 Jul 2016 No recent reports of development identified for preclinical development in Non-small-cell-lung-cancer in Germany (Intradermal, Injection)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top